Using Sensitivity Analysis to Simplify the Virus Safety Factor Calculation in the Manufacture of Biopharmaceuticals

References

1. 1.↵
   1. Zhang J.

   Mammalian Cell Culture for Biopharmaceutical Production. In Manual of Industrial Microbiology and Biotechnology; ASM Press: Washington, DC, 2010; pp 157–178.
2. 2.↵
   International Conference for Harmonisation, Quality Guideline Q5A(R1): Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin. ICH Geneva, 1997.
3. 3.↵
   Committee for Proprietary Medicinal Products. Note for Guidance on Virus Validation Studies: The Design, Contribution, and Interpretation of Studies Validating the Inactivation and Removal of Viruses, Revised; BWP/268/95; EMA: London, 1996.
4. 4.↵
   Committee for Proprietary Medicinal Products. Guideline on Virus Safety Evaluation of Biotechnological Investigational Medicinal Products; EMEA/CHMP/BWP/398498/2005; EMA: London, 2009.
5. 5.↵
   U.S. Pharmacopeial Convention. General Chapter <1050.1> Design, Evaluation, and Characterization of Viral Clearance Procedures. In USP 40—NF 35, USP: Rockville, MD, 2017.
6. 6.↵
   1. Shukla A. A.,
   2. Aranha H.

   Viral Clearance for Biopharmaceutical Downstream Processes. Pharm. Bioprocess. 2015, 3 (2), 127–138.

   OpenUrl
7. 7.↵
   1. Shepherd A. J.,
   2. Wilson N. J.,
   3. Smith K. T.

   Characterisation of Endogenous Retrovirus in Rodent Cell Lines Used for Production of Biologicals. Biologicals 2003, 31 (4), 251–260.

   OpenUrlCrossRefPubMedWeb of Science
8. 8.↵
   1. Anderson K. P.,
   2. Low M.-A. L.,
   3. Lie Y. S.,
   4. Keller G.-A.,
   5. Dinowitz M.

   Endogenous Origin of Defective Retroviruslike Particles from a Recombinant Chinese Hamster Ovary Cell Line. Virology 1991, 181 (1), 305–311.

   OpenUrlPubMed
9. 9.↵
   1. Anderson K. P.,
   2. Lie Y. S.,
   3. Low M. A.,
   4. Williams S. R.,
   5. Wurm F. M.,
   6. Dinowitz M.

   Defective Endogenous Retrovirus-like Sequences and Particles of Chinese Hamster Ovary Cells. Dev. Biol. Stand. 1991, 75, 123–132.

   OpenUrlPubMed
10. 10.↵
    1. Sipple P.,
    2. Nguyen T.,
    3. Patel K.,
    4. Jaffe N.,
    5. Chen Y.,
    6. Khetan A.

    Suitability of a Generic Virus Safety Evaluation for Monoclonal Antibody Investigational New Drug Applications. Biotechnol. Prog. 2019, 35 (5), e2850.

    OpenUrl
11. 11.↵
    R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria; 2020. https://www.R-project.org/.
12. 12.
    1. Brorson K.,
    2. Krejci S.,
    3. Lee K.,
    4. Hamilton E.,
    5. Stein K.,
    6. Xu Y.

    Bracketed Generic Inactivation of Rodent Retroviruses by Low pH Treatment for Monoclonal Antibodies and Recombinant Proteins. Biotechnol. Bioeng. 2003, 82 (3), 321–329.

    OpenUrlCrossRefPubMed
13. 13.
    1. Chen Q.

    Viral Clearance Using Traditional, Well-Understood Unit Operations (Session I): Low-pH Inactivation. PDA J. Pharm. Sci. Technol. 2014, 68 (1), 17–22.

    OpenUrlFREE Full Text
14. 14.
    1. Durno L.,
    2. Tounekti O.

    Viral Inactivation: Low pH and Detergent. PDA J. Pharm. Sci. Technol. 2015, 69 (1), 163–172.

    OpenUrlFREE Full Text
15. 15.
    1. Ma J.,
    2. Roush D.

    Session 1.1: Viral Clearance Using Traditional, Well-Understood Unit Operations: Low pH and Detergent Viral Inactivation. PDA J. Pharm. Sci. Technol. 2016, 70 (5), 410–416.

    OpenUrlFREE Full Text
16. 16.
    1. Chinniah S.,
    2. Hinckley P.,
    3. Connell-Crowley L.

    Characterization of Operating Parameters for XMuLV Inactivation by Low pH Treatment. Biotechnol. Prog. 2016, 32 (1), 89–97.

    OpenUrl
17. 17.
    1. Mattila J.,
    2. Clark M.,
    3. Liu S.,
    4. Pieracci J.,
    5. Gervais T. R.,
    6. Wilson E.,
    7. Galperina O.,
    8. Li X.,
    9. Roush D.,
    10. Zoeller K.,
    11. Brough H.,
    12. Simpson-Platre C.

    Retrospective Evaluation of Low-pH Viral Inactivation and Viral Filtration Data from a Multiple Company Collaboration. PDA J. Pharm. Sci. Technol. 2016, 70 (3), 293–299.

    OpenUrlAbstract/FREE Full Text
18. 18.
    ASTM International. ASTM E2888–12 Standard Practice for Process for Inactivation of Rodent Retrovirus by pH. ASTM: West Conshocken, PA, 2012.
19. 19.
    ASTM International. ASTM E3042-16 Standard Practice for Process Step to Inactivate Rodent Retrovirus with Triton X-100 Treatment. ASTM: West Conshohocken, PA, 2016.
20. 20.
    1. Conley L.,
    2. Tao Y.,
    3. Henry A.,
    4. Koepf E.,
    5. Cecchini D.,
    6. Pieracci J.,
    7. Ghose S.

    Evaluation of Eco-Friendly Zwitterionic Detergents for Enveloped Virus Inactivation. Biotechnol. Bioeng. 2017, 114 (4), 813–820.

    OpenUrl
21. 21.
    1. Curtis S.,
    2. Lee K.,
    3. Blank G. S.,
    4. Brorson K.,
    5. Xu Y.

    Generic/Matrix Evaluation of SV40 Clearance by Anion Exchange Chromatography in Flow-through Mode. Biotechnol. Bioeng. 2003, 84 (2), 179–186.

    OpenUrlPubMed
22. 22.
    1. Strauss D. M.,
    2. Lute S.,
    3. Tebaykina Z.,
    4. Frey D. D.,
    5. Ho C.,
    6. Blank G. S.,
    7. Brorson K.,
    8. Chen Q.,
    9. Yang B.

    Understanding the Mechanism of Virus Removal by Q Sepharose Fast Flow Chromatography during the Purification of CHO-Cell Derived Biotherapeutics. Biotechnol. Bioeng. 2009, 104 (2), 371–380.

    OpenUrlPubMed
23. 23.
    1. Strauss D. M.,
    2. Cano T.,
    3. Cai N.,
    4. Delucchi H.,
    5. Plancarte M.,
    6. Coleman D.,
    7. Blank G. S.,
    8. Chen Q.,
    9. Yang B.

    Strategies for Developing Design Spaces for Viral Clearance by Anion Exchange Chromatography during Monoclonal Antibody Production. Biotechnol. Prog. 2010, 26 (3), 750–755.

    OpenUrlPubMed
24. 24.
    1. Connell-Crowley L.,
    2. Larimore E. A.,
    3. Gillespie R.

    Using High Throughput Screening to Define Virus Clearance by Chromatography Resins. Biotechnol. Bioeng. 2013, 110 (7), 1984–1994.

    OpenUrl
25. 25.
    1. Roush D.

    Viral Clearance Using Traditional, Well-Understood Unit Operations: Session 1.2. Anion Exchange Chromatography; and Session 1.3. Protein A Chromatography. PDA J. Pharm. Sci. Technol. 2015, 69 (1), 154–162.

    OpenUrlFREE Full Text
26. 26.
    1. Cai K.,
    2. Anderson J.,
    3. Orchard J. D.,
    4. Afdahl C. D.,
    5. Dickson M.,
    6. Li Y.

    Virus Removal Robustness of Ion Exchange Chromatography. Biologicals 2019, 58, 28–34.

    OpenUrl
27. 27.
    1. Connell-Crowley L.,
    2. Nguyen T.,
    3. Bach J.,
    4. Chinniah S.,
    5. Bashiri H.,
    6. Gillespie R.,
    7. Moscariello J.,
    8. Hinckley P.,
    9. Dehghani H.,
    10. Vunnum S.,
    11. Vedantham G.

    Cation Exchange Chromatography Provides Effective Retrovirus Clearance for Antibody Purification Processes. Biotechnol. Bioeng. 2012, 109 (1), 157–165.

    OpenUrlPubMed
28. 28.
    1. Miesegaes G.,
    2. Lute S.,
    3. Brorson K.

    Analysis of Viral Clearance Unit Operations for Monoclonal Antibodies. Biotechnol. Bioeng. 2010, 106 (2), 238–246.

    OpenUrlPubMed
29. 29.
    1. Gefroh E.,
    2. Dehghani H.,
    3. McClure M.,
    4. Connell-Crowley L.,
    5. Vedantham G.

    Use of MMV as a Single Worst-Case Model Virus in Viral Filter Validation Studies. PDA J. Pharm. Sci. Technol. 2014, 68 (3), 297–311.

    OpenUrlAbstract/FREE Full Text
30. 30.
    1. Chen D.

    Viral Clearance Using Traditional, Well-Understood Unit Operations (Session I): Virus-Retentive Filtration. PDA J. Pharm. Sci. Technol. 2014, 68 (1), 38–50.

    OpenUrlFREE Full Text
31. 31.
    1. Stuckey J.,
    2. Strauss D.,
    3. Venkiteshwaran A.,
    4. Gao J.,
    5. Luo W.,
    6. Quertinmont M.,
    7. O'Donnell S.,
    8. Chen D.

    A Novel Approach to Achieving Modular Retrovirus Clearance for a Parvovirus Filter. Biotechnol. Prog. 2014, 30 (1), 79–85.

    OpenUrlCrossRef
32. 32.
    1. Chen Q.,
    2. Chen D.

    Viral Clearance of Traditional Unit Operations: Virus-Retentive Filtration. PDA J. Pharm. Sci. Technol. 2015, 69 (1), 142–153.

    OpenUrlFREE Full Text
33. 33.
    Millipore. Virus Retention Performance of Viresolve Pro Devices under a Range of Processing Conditions. Application Note, 2019.